Phenotypic Assessment and the Discovery of Topiramate

Bruce E. Maryanoff^*

Baruch S. Blumberg Institute, 3805 Old Easton Road, Doylestown, Pennsylvania 18902, United States

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States

ACS Med. Chem. Lett., 2016, 7 (7), pp 662–665

DOI: 10.1021/acsmedchemlett.6b00176

Publication Date (Web): June 13, 2016

Copyright © 2016 American Chemical Society

*E-mail: bmaryano@scripps.edu.

ACS Editors' Choice - This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.

Abstract

Abstract Image

The role of phenotypic assessment in drug discovery is discussed, along with the discovery and development of TOPAMAX (topiramate), a billion-dollar molecule for the treatment of epilepsy and migraine.

Keywords:

anticonvulsant; Drug discovery; epilepsy; phenotype; topiramate;

View: ACS ActiveView PDF | PDF | PDF w/ Links | Full Text HTML

Citing Articles
Related Content

Citation data is made available by participants in CrossRef's Cited-by Linking service. For a more comprehensive list of citations to this article, users are encouraged to perform a search in SciFinder.

Underexplored Opportunities for Natural Products in Drug Discovery
Bart L. DeCorte
Journal of Medicinal Chemistry 2016 59 (20), 9295-9304
Abstract | Full Text HTML | PDF | PDF w/ Links

Other ACS content by these authors:

Bruce E. Maryanoff

Related Content:

Innovations in Medicinal Chemistry
ACS Medicinal Chemistry Letters
Liotta (Editor-in-Chief)
2016 7 (7), pp 656–657
Abstract | Full Text HTML | PDF w/ Links | Hi-Res PDF
Unusual Amino Acids in Medicinal Chemistry
Journal of Medicinal Chemistry
Blaskovich
2016 59 (24), pp 10807–10836
Abstract: Unusual amino acids are fundamental building blocks of modern medicinal chemistry. The combination of readily functionalized amine and carboxyl groups attached to a chiral central core along with one or two potentially diverse side chains provides a ...
Abstract | Full Text HTML | PDF w/ Links | Hi-Res PDF
Fragment-to-Lead Medicinal Chemistry Publications in 2015
Journal of Medicinal Chemistry
Johnson, Erlanson, Murray, and Rees
2017 60 (1), pp 89–99
Abstract: Fragment-based drug discovery (FBDD) is now well-established as a technology for generating new chemical leads and drugs. This Miniperspective provides a tabulated overview of the fragment-to-lead literature published in the year 2015, together with a ...
Abstract | Full Text HTML | PDF w/ Links | Hi-Res PDF
No Denying It: Medicinal Chemistry Training Is in Big Trouble
Journal of Medicinal Chemistry
Rafferty
2016 59 (24), pp 10859–10864
Abstract: There has been little consensus between the pharmaceutical industry and academic communities concerning the best approach to train medicinal chemists for drug discovery. For decades the pharmaceutical industry has shown preference for synthetic organic ...
Abstract | Full Text HTML | PDF w/ Links | Hi-Res PDF
A Versatile Method to Determine the Cellular Bioavailability of Small-Molecule Inhibitors
Journal of Medicinal Chemistry
Teuscher, Zhang, and Ji
2017 60 (1), pp 157–169
Abstract: The determination of the cellular bioavailability of small-molecule inhibitors is a critical step for interpreting cell-based data and guiding inhibitor optimization. Herein, a HPLC-MS based protocol was developed to determine inhibitor cellular ...
Abstract | Full Text HTML | PDF w/ Links | Hi-Res PDF
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease
Journal of Medicinal Chemistry
Scott, Li, Brunskill, Chen, Cox, Cumming, Forman, Gilbert, Hodgson, Hyde, Jiang, Iserloh, Kazakevich, Kuvelkar, Mei, Meredith, Misiaszek, Orth, Rossiter, Slater, Stone, Strickland, Voigt, Wang, Wang, Wu, Greenlee, Parker, Kennedy, and Stamford
2016 59 (23), pp 10435–10450
Abstract: Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the ...
Abstract | Full Text HTML | PDF w/ Links | Hi-Res PDF